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Introduction 
Diabetes Mellitus  (DM) is  a metabolic  disorder of  the 
body, in which either a sufficient amount of insulin in the 
body  does  not  exist  or  the  existing  insulin  may  not 
perform  his  task  properly.
1  Diabetic  retinopathy  (DR), 
the most important ocular complication in patients with 
DM is the leading cause of blindness in patients aged 20- 
65 years in the United States and in individuals between 
the ages of 30 and 64 in the United Kingdom; in which, 
it  accounts  for  nearly  12%–14%  of  new  cases  of 
blindness  resulting  from  all  causes.
2-5  Retinal  edema 
threatening  or  involving  the  macula  is  an  important 
visual outcome of abnormal retinal vascular permeability 
in DR. The diabetic macular edema (DME) is diagnosed 
by slit-lamp biomicroscopy of the posterior pole. DME is 
caused by a breakdown in the blood-retinal barrier that 
lead to the accumulation of fluid in the space between 
the layers of retina in the macular area.
5 Data from the 
Early  Treatment  Diabetic  Retinopathy  Study  (ETDRS) 
showed  that  focal  laser  photocoagulation  of  clinically 
significant diabetic macular edema (CSME) substantially 
reduces  the  risk  of  visual  loss.  Focal  treatment  also 
increases  the  chance  of  visual  improvement,  decreases 
the frequency  of persistent  macular edema,  and  causes 
only minor visual field losses. Therefore the presence or 
the absence of the CSME is the most important and the 
only specific factor defining the need to the treatment.
6 
Laser treatment prevents vision loss, but does not have a 
significant  effect  on  improving  vision.  This  problem 
evokes the researchers for alternative therapies. The use 
of intravitreal injection of the steroid compound in some 
studies  has  reported  good  results.
7,8  Also  intravitreal 
injection of the Bevacizumab (Avastin) has showed good 
results.
9 Calcium  dobesilate  (Doxium)  is  an  anti-
oxidative and angio-protective drug that decreases edema 
by  regulating  and  improvement  the  physiological 
function.  Recent  studies  have  shown  that  Doxium  is  a 
potent  antioxidant,  particularly  against  the  highly 
damaging  hydroxyl  radical.  In  addition,  it  improves 
diabetic endothelial dysfunction, reduces apoptosis, and 
slows  vascular  cell  proliferation.
10,11  Doxium  recently 
remains  the  object  of  interest  in  treatment  of  diabetic 
retinopathy,  but  various  results  have  been  reported  by 
different  studies  performed  on  reducing  the  macular 
edema by Doxium.
11-14 Thus, this study was conducted to 
assess the effect of oral Doxium adding to macular laser 
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Abstract 
Purpose: To evaluate the effect of oral calcium dobesilate (Doxium) on macular thickness 
in clinically significant macular edema (CSME). 
Methods: Overall, 71 eyes of 40 patients with non-proliferative diabetic retinopathy and 
clinically  significant  macular  edema  were  included.  All  patients  were  received  laser 
treatment  for  macular  edema.  Coherence  optical  tomography  was used  to  determine  the 
retinal thickness. Patients were randomized into two groups: group A received three Doxium 
capsule daily and group B received three placebo capsule daily for six months.  
Results: The mean macular thickness before and after treatment in the group A was 340 and 
257 micrometers respectively (24.5% reduced), and in the group B was 336 micrometers 
and  263  micrometers  respectively  (21.5%  reduced).  Macular  thickness  significantly 
decreased after treatment in both groups and the reduction in group A is higher but the 
difference of reduction between the two groups was not statistically significant (P>0.05). 
Conclusion: In respect to the effect of adding oral Doxium to Laser Photocoagulation on the 
macular thickness in patients with diabetic macular edema, this study showed no statistically 
significant difference between Doxium and placebo.  
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photocoagulation  on  the  macular  thickness  in  patients 
with CSME. 
 
Materials and Methods 
Study design and population 
A  randomized,  single  blinded,  placebo-controlled  trial 
was  conducted  on  patients  with  type  II  DM  that  had 
diabetic  retinopathy  and  referred  to  the  ophthalmology 
clinic, Imam Khomeini Hospital, Ahvaz, Iran from 2012-
07-22 to 2013-01-19. The IRCT registration number of 
the study was: IRCT2012091610852N1. 
 
Inclusion criteria 
All  patients  with  non-proliferative  diabetic  retinopathy 
and CSME which at least have 20/200 visual acuity were 
included.  
 
Exclusion criteria 
Patients  with  the  history  of  previous  treatment  for  a 
CSME such as macular laser and intravitreal injection of 
Avastin,  posterior  segment  trauma,  the  need  for  the 
further  eye  surgery  such  as  vitreo-retinal  surgery  or 
cataract,  cases  of  non-feasible  clinical  observation, 
optical  coherence  tomography  (OCT)  and  fluorescein 
angiography (FA) such as severe opacities of the media, 
the  existence  of  a  previous  vascular  pathology  of  the 
retina or age-related macular degeneration, a history of 
previous  intraocular  surgery,  visual  acuity  less  than 
20/200  and  presence  of  macular  ischemia  in  FA  were 
excluded. 
 
Intervention 
The  demographic  profile  of  patients  includes  age, 
gender,  occupation,  history  of  DM  and  smoking,  were 
collected.  Then,  visual  acuity  of  the  patients  was 
measured  using  the  Snellen  chart.  Patients  were 
examined with a Slit-Lamp (Topcon; Tokyo Optical Co., 
Ltd., Tokyo, Japan) and fundoscopy was done with the 
Volk's 78D and 90D lenses. Intraocular pressure (IOP, 
mmHg)  was  measured  using  a  Goldmann  applanation 
tonometer. FA (Topcon; Tokyo Optical Co., Ltd., Tokyo, 
Japan)  of  the  retina  was  performed  for  all  patients  to 
monitor the areas of leakage and the macular thickness 
was measured using OCT (Topcon; Tokyo Optical Co., 
Ltd.,  Tokyo,  Japan).  Then  the  patients  by  simple 
randomization were divided into two groups, group A; 
receiving three capsules of Doxium 500 milligram daily 
and  group  B;  receiving  three  capsules  of  placebo 
(containing starch with same sizes and color as Doxium 
capsules) daily for six-month. All patients were received 
classic laser treatment for macular edema, and six-month 
later again undergone the OCT to measure the macular 
thickness. Macular laser therapy was performed based on 
the ETDRS chart and algorithm using standard protocol 
with green laser set up every laser point with 50 to 100 
micrometers. The emission duration was 0.1 second and 
the  power  was  set  right  with  the  proper  laser  lighting 
effect, and the area of the macula has exposed, so that at 
least 500 micrometers  from the edge  of the optic  disk 
and 500 micrometers away from the center of fovea. The 
laser  energy  was  started  at  50  mV  and  gradually 
increased until a modest and proper white spot revealed 
in the macula. 
 
Outcome 
Primary outcome; macular thickness 
Secondary  outcomes:  visual  acuity  and  intraocular 
pressure 
 
Statistical analysis 
After gathering information, data were analyzed by SPSS 
19.0. Descriptive statistics (mean and standard deviation) 
were  used  to  describe  the  desired  variables.  Then  to 
determine  the  relationship  between  the  variable  T-test 
and  paired  T-test  and  ANOVA  were  used.  Significant 
level was considered equal or lesser than 0.05. 
 
Results 
Overall, 40 patients (mean age of 53.55 ± 8.8, rang of 
36-72 years) were studied, which 22 patients (55%) were 
male and 18 patients (45%) were female. There was no 
significant difference between groups A and B in term of 
age (54 ± 9.5 vs. 53.1 ± 9.8, respectively). In this study, 
total of 71 eyes were studied (36 eyes in group A and 35 
eyes in group B), that 33 (46.5%) and 38(53.5%) were 
the right and left eyes respectively. In both groups after 
treatment the macular thickness reduced so that in group 
A the reduction was 80 micrometers (24.5%) and in the 
group B it was 75 micrometers (21.5%). The difference 
of  changes  in  the  macular  thickness  between  the  two 
groups  was  not  statistically  significant  (Table  1).  Six 
months after treatment, nine-eye (25%) in groups A and 
ten-eye (28.5%) in groups B need laser retreatment. The 
difference between the two groups was not statistically 
significant. The difference of visual acuity increase and 
the change of the mean IOP before and after treatment 
had  no  statistically  significant  difference  between  the 
two groups (Table 1). 
 
Table 1. Comparing the variables of interest before and after treatment with oral Doxium and macular laser 
Variables  
Before treatment (Mean ± SD)  After treatment (Mean ± SD)  
Group A   Group B   P-value   Group A   Group B   P-value  
Macular thickness, μm   340.8 ± 85.46   336.05 ± 81.27   0.81   257.44 ± 55.04   263.34 ± 66.62   0.68  
Visual acuity, Log Mar   0.595 ± 0.192   0.567 ± 0.199   0.54   0.509 ± 0.166   0.495 ± 0.213   0.76  
IOP, mmHg   13.52 ± 1.44   13.91 ± 1.59   0.28   13.00 ± 1.37   13.25 ± 1.55   0.40  
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Discussion 
Diabetic  maculopathy  is  one  of  the  most  important 
causes  of  vision  loss  among  people  around  the  world 
today.  Though  laser  photocoagulation  remains  as  the 
gold standard therapy for diabetic macular edema, only a 
slight  visual  improvement  has  been  reported  following 
laser therapy. Therefore, different methods of treatment 
besides  laser  therapy  are  used  to  treat  DME  more 
effectively. In this study we assessed the effect of adding 
oral Doxium to macular photocagulation on the macular 
thickness  in  patients  with  DME.  In  many  studies  the 
effect of Doxium on the DR has been reviewed, but the 
effect  of  this  drug  on  the  macular  thickness  was  less 
evaluated. In the present study reducing macular edema 
evaluated with macular thickness measurement using the 
OCT  as  a  more  accurate  method.  In  most  studies  the 
effect  of  Doxium  on  DR  investigated  and  none  of  the 
studies has considered the macular thickness using OCT. 
Rota et al. studied the effect of Doxium on the  retinal 
albumin  leakage  in  streptozotocin-diabetic  rats  for  10 
days, and suggested that this drug stabilizes blood-retinal 
barrier  in  diabetic  retinopathy.
12  Haritoglou  et  al. 
investigated the effect of Doxium in the diabetic patients 
with  mild-to-moderate  non-proliferative  diabetic 
retinopathy, and reported that this drug  did not reduce 
the risk of development of CSME.
13 Our study was in 
line  with  Haritoglou  et  al.  study  and  revealed  that 
Doxium didn’t reduce the diabetic macular edema, but 
the difference was the same as our study. We measured 
the  macular  thickness  using  OCT  before  and  after 
treatment but Haritoglou et al. just studied the effect of 
Doxium in  terms  of the  risk  of progression  of  clinical 
significant macular edema.  
Fesharaki and Modaresi, measured the effect of Doxium 
on  the  visual  acuity  and  surface  area  of  retinal 
hemorrhage  in  patients  with  non-proliferative  diabetic 
retinopathy,  and  claimed  that  this  drug  (250  mg  two 
tablets per day for six months) may has a positive effect 
on  visual  activity.
14  In  contrast  with  Fesharaki  and 
Modaresi,  in  our  study,  Doxium  has  no  effect  on  the 
visual improvement of the patients.  
Ribeiro et al. studied the effect of Doxium on the blood-
retinal  barrier  (BRB)  permeability  in  early  diabetic 
retinopathy, and showed that the dosage of two grams of 
this  drug  daily  for  two-year  has  a  significantly  better 
activity  on  prevention  of  BRB  disruption,  with  a  very 
good tolerance.
15  
 Vojnikovic studied the effect of oral Doxium on the 79 
non-insulin-dependent  diabetic  subjects  with  early 
retinopathy and open-angle glaucoma, and suggested that 
this drug reduces blood hyperviscosity and lowers IOP, 
with a beneficial effect on retinal state and visual fields.
16 
Our  study  revealed  the  oral  Doxium  has  no  effect  on 
IOP; of course we excluded the patients with a history of 
glaucoma and high IOP, and only the effect of this drug 
on  the  IOP  of  diabetic  patients  without  a  history  of 
glaucoma were evaluated.  
Stamper  et  al.  evaluates  the  efficacy  of  Doxium  for 
treating non-proliferative diabetic retinopathy by clinical 
examination, FA and fundus photography and failed to 
demonstrate any beneficial effect of Doxium.
17  
 
Conclusion  
Doxium has no statistically significant effect on macular 
thickness,  visual  acuity  and  intraocular  pressure  in 
patients  with  DME  treating  by  macular  laser 
photocoagulation. 
One  of  the  advantages  of  the  present  study  was  the 
quantitative observation of the macular thickness using 
OCT  as  a  more  accurate  method.  But  the  major 
weaknesses in our study were the short follow-up period, 
the high cost of supplying the drug, and no observation 
of  the  effect  of  the  drug  on  the  systemic  blood  sugar 
levels. Further studies in the longer follow-up period and 
larger sample size are recommended. 
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